Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Approvals & launches

Larimar completes BLA submission for nomlabofusp in Friedreich's ataxia, seeking accelerated approval

The US biotech is relying on skin frataxin as a novel surrogate endpoint and expects the FDA's filing decision in early 2027, with approval targeted for mid-2027.

16 Nov 2026 · Larimar Therapeutics, Inc. LRMR · Company news

Larimar Therapeutics has completed its rolling Biologics License Application (BLA) to the US Food and Drug Administration for nomlabofusp, seeking accelerated approval in adults and children with Friedreich's ataxia. The company disclosed the milestone on 16 November 2026 alongside its third-quarter 2026 update.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Larimar Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Approvals & launchesAll →